Lars Wortmann

Lars Wortmann

Boehringer Ingelheim - / United States
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4385610
person_outline Lars Wortmann's MOST POPULAR ARTICLES
1-) Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interactionRC Hillig, B Sautier, J Schroeder, D Moosmayer, A Hilpmann, ...Proceedings of the National Academy of Sciences 116 (7), 2551-2560, 20192422019
2-) Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosisA Santamaria, R Neef, U Eberspächer, K Eis, M Husemann, D Mumberg, ...Molecular biology of the cell 18 (10), 4024-4036, 20072312007
3-) The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage–inducing or repair–compromising therapies in preclinical cancer modelsAM Wengner, G Siemeister, U Lücking, J Lefranc, L Wortmann, P Lienau, ...Molecular cancer therapeutics 19 (1), 26-38, 20201742020
4-) Recovery of Carbonyl Compounds from N,N-DialkylhydrazonesD Enders, L Wortmann, R PetersAccounts of chemical research 33 (3), 157-169, 20001712000
5-) Prey for the proteasome: targeted protein degradation—a medicinal chemist\'s perspectiveLM Luh, U Scheib, K Juenemann, L Wortmann, M Brands, PM CrommAngewandte Chemie International Edition 59 (36), 15448-15466, 20201492020